Glenmark Pharma to Launch Generic ADHD Drug in US Market by May 2025

Shares of Glenmark Pharmaceuticals are in focus following an announcement that its U.S. subsidiary is set to launch a generic version of a commonly prescribed ADHD medication. In an exchange filing dated Wednesday, April 16, the company stated that the distribution of the tablets will begin in May 2025.

Bioequivalent to Adderall Tablets

Glenmark will introduce dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets—a combination known as mixed salts of a single-entity amphetamine product. The tablets will be launched in 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg strengths.

The medication is the bioequivalent and therapeutically equivalent to the reference listed drug, Adderall Tablets, manufactured by Teva Women’s Health, Inc. This equivalence ensures that the product provides the same clinical benefit as the branded version.

According to IQVIA sales data for the 12 months ending February 2025, Adderall tablets in these specific strengths recorded annual sales of approximately $421.7 million in the U.S. market.

Addressing Critical Drug Shortages

Commenting on the launch, Marc Kikuchi, President and Business Head for North America at Glenmark, said “Glenmark is very pleased to be able to help alleviate the shortage this country has been facing with this upcoming launch.”

He emphasised the significance of the product in the U.S. healthcare landscape, highlighting that the medicine is a highly prescribed treatment for Attention Deficit Hyperactivity Disorder (ADHD).

Stock Performance

Despite the positive development, Glenmark Pharma shares ended the previous trading session 1.61% lower at ₹1,354.8 apiece. The stock has experienced a downturn in recent months, having declined nearly 22% over the last six months.

Conclusion 

Glenmark’s upcoming launch of its generic Adderall-equivalent marks a strategic move into a high-demand segment of the U.S. pharmaceutical market. With a focus on addressing ongoing ADHD medication shortages, the company aims to strengthen its North American presence. This development could also offer a much-needed boost to its stock performance, which has seen a notable decline in recent months.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.